GlassScriptPhysician profile
Rosaura Licea
NPI 1548299225
$8,961.30
in general payments reported to CMS, 2019-2025
23 companies · $2,252 in 2025
The $2,252 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $569 · 2021: $1,160 · 2022: $1,191 · 2023: $1,172 · 2024: $1,754 · 2025: $2,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,178.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,365.35 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,752.53 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $679.65 | 2019-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $636.83 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $511.61 | 2020-2025 | Jardiance |
| Amgen INC. | $498.09 | 2023-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $425.94 | 2022-2024 | |
| Abbvie INC. | $423.20 | 2023-2025 | |
| Glaxosmithkline, LLC. | $354.32 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Medtronic, INC. | $241.73 | 2022 | |
| Abbott Laboratories | $237.72 | 2023-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $207.22 | 2019 | |
| Pfizer INC. | $148.84 | 2023-2025 | |
| Madrigal Pharmaceuticals | $143.57 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $139.85 | 2024-2025 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qiagen, LLC | $40.91 | 2020 | |
| Cranial Technologies, INC | $40.69 | 2024-2025 | Doc Band |
| Sunovion Pharmaceuticals INC. | $24.99 | 2019 | |
| Sanofi Pasteur INC. | $21.75 | 2020 | |
| Phadia US INC. | $19.58 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.16 | 2022 | |
| Hologic Sales and Service, LLC | $14.17 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosaura Licea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.